openPR Logo
Press release

An exclusive speaker interview with twoXAR CEO for SMi’s 3rd Annual Ophthalmic Drugs Conference 2019

09-19-2019 04:26 PM CET | Health & Medicine

Press release from: SMI

Ophthalmic Drugs Conference 2019

Ophthalmic Drugs Conference 2019

SMi Group Reports: CEO of twoXAR to present at SMi’s Ophthalmic Drugs conference commencing on 18th- 20th November 2019, in London

The Ophthalmic Drugs conference is taking place on the 18th- 20th November 2019 in London. The three-day agenda will focus on ‘Exploring the future of ocular drug development’, which unpacks new discoveries in the treatment of ocular rare disease, innovations in gene therapy, the challenges in drug delivery through a complex barrier, patient comfort, and regulatory compliance which make up such core components within the Ophthalmic Drug sphere.

As the event draws closer, SMi caught up with twoXAR CEO, Andrew Radin as a speaker for Europe’s leading Ophthalmic Drugs conference. Andrew is dedicated to transforming the drug discovery process through the power of Artificial Intelligence. Prior to twoXAR, Andrew held CTO roles at several early-stage companies. Andrew studied biomedical informatics at Stanford University’s SCPD graduate program and holds MS and BS degrees in computer science from Rochester Institute of Technology.

For those interested in attending, there is an early bird saving of £100 for bookings made by 30th September available to download at www.ophthalmicdrugs.com/openpr6

Snapshot of Andrew’s interview:

The ophthalmic drugs market has matured greatly over recent years, what are the key significant developments you have noticed with respect to AI over the past year?

“AI in drug discovery has moved from a niche concept to becoming more mainstream. There is now acceptance that AI can help change the drug discovery process in a meaningful way. This has translated into more partnerships between drug developers and AI drug discovery companies, such as the partnership between Santen and twoXAR, which is specifically focused on treatments for glaucoma…”

What do you personally see as the greatest challenge to overcome in the field of Ophthalmic Drugs at the moment?

“The challenge in ophthalmic drug discovery, and drug discovery in general, is that pipelines are shrinking, and it takes years for a drug candidate to reach the IND stage. R&D efficiency has also been declining for many years now, which means there is high spend on drug discovery with few gains on new and effective molecules…”

For the full speaker interview, speaker line-up, as well as the latest brochure and past attendees, go to the download at www.ophthalmicdrugs.com/openpr6

Ophthalmic Drugs Conference
18th – 20th November 2020
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
EXPERIMENTICA | ProMed Pharma

Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / amalick@smi-online.co.uk

Media enquiries contact Neill Howard +44 (0) 207 827 6164 / nhoward@smi-online.co.uk

--END—

------------------------------------------------------------------------------------

45 Curlew Street

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release An exclusive speaker interview with twoXAR CEO for SMi’s 3rd Annual Ophthalmic Drugs Conference 2019 here

News-ID: 1835276 • Views: 321

More Releases from SMI

Senior US officials from fuel policy teams and combat wings to present at Milita …
SMi reports: Senior US officials will be presenting at the 21st Annual Military Airlift Air-to-Air Refuelling conference in Seville, this December Air-to-air refuelling remains a key mission multiplier, utilised extensively in Operation Inherent Resolve to extend flight times for bombing runs against ISIS. As the US Air Force explores the greater utilisation of commercial refuellers for CONUS operations to free military assets for combat and international deployment there is a critical
Senior experts to discuss Naval Mine Countermeasures at Unmanned Maritime System …
The challenge posed by potential adversary mining capabilities is real and growing. For all navies, there is only one way to completely “Take the sailor out of the minefield,” and that is to leverage unmanned technologies to hunt and destroy mines from a distance.* By embracing technological advancements in unmanned systems, such as UUVs and USVs, they could sweep large portions of the sea while minimizing the risk to sailors. For
Military Robotics and Autonomous Systems 2020 announced as a Virtual Event
SMi Reports: Due to the ongoing challenges surrounding COVID-19, Military Robotics and Autonomous Systems in September will now run as a virtual event. With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the 3rd annual Military Robotics and Autonomous Systems Conference on the 2nd-3rd September 2020 into a fully interactive virtual meeting. All attendance by military and government will be free of charge
04-07-2020 | Health & Medicine
SMI
Associates of Cape Cod Webinar on Recombinant Chromogenic Assay as Alternate Met …
SMi Reports: Associates of Cape Cod to host an online webinar taking place on Wednesday 29th April 2020. SMi Group is delighted to announce a free webinar led by Associates of Cape Cods on 'Recombinant Chromogenic Assay as Alternate Methods for Bacterial Endotoxins Test (BET)' taking place on 29th April 2020 at 10am EDT (3pm BST - UK time). The webinar will aim to review the global perspective on the use

All 5 Releases


More Releases for Ophthalmic

Ophthalmic Eye Shield Market Segmentation By Material type Aluminium Ophthalmic …
Eye shields are advised for use in the eye while a periorbital surgery to avoid any injury to the globe. Ophthalmic eye shields are used for postoperative ocular protection. Ophthalmic eye shields protect the cornea and retina while any eye surgery or laser treatment. Ophthalmic eye shields are highly preferred for cataract surgeries in the elder population and blepharitis correction especially for children. According to WHO, The World Health Organization,
Ophthalmic Viscosurgical Devices Market Snapshot During 2025
The global ophthalmic viscosurgical devices market is driven by the growing number of cataract procedures held worldwide. In addition to this, the lack of awareness among people regarding the need for regular eye checkups will also heighten the demand for ophthalmic viscosurgical devices in the future. The tendency to procrastinate eye checkups and thus, delayed detection of eye problems will aggravate the demand for these devices, fueling the market’s growth. The
Ophthalmic Lasers Market - Global Industry Analysis 2025
Ophthalmic lasers are used for treatment of wide range of eye problems. Significant accuracy, low-cost, safe procedure, and convenient ophthalmic tools has increased the demand for ophthalmic lasers. Patients prefer ophthalmic lasers treatment due to pain free procedures and easy availability on an outpatient basis. The main constituents of an ophthalmic laser system include foot pedal, laser console, and laser delivery system. The laser energy is transmitted to the patient’s eye
Ophthalmic Lasers Market- Growth Factors
The global ophthalmic lasers market is fragmented in nature, with top five vendors accounting for a modest 35.0% share in it in 2015. The market is characterized by moderate competition. However, in the foreseeable future, competition in the market is likely to heat up on the back of pharmaceutical companies entering it sensing an opportunity in the rising demand for effective surgical products because of the increasing number of ophthalmic
Excimer and Femtosecond Ophthalmic Lasers Market
Global excimer and femtosecond ophthalmic lasers market will expand at a CAGR of 5% over the forecast period, 2016-2026. The global excimer and femtosecond ophthalmic lasers market is expected to witness stable growth in 2016, reaching a value of US$ 666 Mn in terms of revenues. Excimer laser systems will continue to outsell femtosecond lasers. North America will remain the top market, whereas Asia Pacific (excluding China and Japan) is anticipated
Ophthalmic Devices Market - Global Industry Insights, 2025
Ophthalmology refers to a branch of medical sciences that deals with the structural and functional defects of the eye. Ophthalmic devices are medical devices used in the treatment and identification of certain ocular deformities and deficiencies of the eyes. The global ophthalmic devices market is driven by eye disorders such as glaucoma, diabetic retinopathy, macular degeneration, and cataract and vision care devices. Ophthalmic devices are also used in various surgical